Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Non-Hodgkin lymphoma (all types), drawn from the whole corpus: 121 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Relapsed T-cell lymphomas still lack effective options.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Access to CAR-T and bispecifics outside high-income countries.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.
Median progression-free survival 31.
Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0.
Accelerated approval in DLBCL (EPCORE NHL-1)
Glofitamab and epcoritamab, off-the-shelf CD20 x CD3 antibodies, approved for relapsed large B-cell lymphoma.